Poziotinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Poziotinib
Accession Number
DB12114
Type
Small Molecule
Groups
Investigational
Description

Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
HM 781-36B / HM-781-36B
Categories
Not Available
UNII
OEI6OOU6IK
CAS number
1092364-38-9
Weight
Average: 491.34
Monoisotopic: 490.0974741
Chemical Formula
C23H21Cl2FN4O3
InChI Key
LPFWVDIFUFFKJU-UHFFFAOYSA-N
InChI
InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)
IUPAC Name
1-[4-({4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]prop-2-en-1-one
SMILES
COC1=C(OC2CCN(CC2)C(=O)C=C)C=C2C(NC3=CC=C(Cl)C(Cl)=C3F)=NC=NC2=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
25127713
PubChem Substance
347828415
ChemSpider
30687714
ChEMBL
CHEMBL3545154
Wikipedia
Poziotinib

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCancer, Breast1
1, 2CompletedTreatmentHER-2 Positive Advanced Gastric Cancer1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentAdenocarcinoma of Lung Stage IV / HER2 Gene Mutation1
2CompletedTreatmentIncreased Drug Resistance1
2RecruitingPreventionHNSCC / Neoplasms, Head and Neck1
2RecruitingTreatmentCancer, Breast / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentEGFR Exon 20 Mutation / ERBB2 Gene Mutation / Lung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Respiratory and Intrathoracic Organ / Recurrent Lung Non-Small Cell Carcinoma / Stage IV Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2TerminatedTreatmentAdenocarcinoma of Lung Stage IIIB / Adenocarcinoma of Lung Stage IV1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0117 mg/mLALOGPS
logP4.93ALOGPS
logP4.5ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.99ChemAxon
pKa (Strongest Basic)4.49ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.58 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity124.72 m3·mol-1ChemAxon
Polarizability48.59 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
N-acylpiperidines / Aniline and substituted anilines / Anisoles / Dichlorobenzenes / Fluorobenzenes / Alkyl aryl ethers / Aminopyrimidines and derivatives / Imidolactams / Aryl fluorides / Aryl chlorides
show 10 more
Substituents
Quinazolinamine / N-acyl-piperidine / 1,2-dichlorobenzene / Phenol ether / Anisole / Aniline or substituted anilines / Fluorobenzene / Halobenzene / Alkyl aryl ether / Aminopyrimidine
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:23 / Updated on June 04, 2019 07:32